MCID: ANG015
MIFTS: 57

Angioedema

Categories: Skin diseases, Genetic diseases, Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioedema

MalaCards integrated aliases for Angioedema:

Name: Angioedema 12 76 55 6 44 15 73
Quincke's Edema 12 76
Angioneurotic Oedema 12
Angioneurotic Edema 12
Giant Urticaria 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1558
ICD10 33 T78.3
MeSH 44 D000799
NCIt 50 C112175
UMLS 73 C0002994

Summaries for Angioedema

Disease Ontology : 12 A skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues.

MalaCards based summary : Angioedema, also known as quincke's edema, is related to angioedema, hereditary, type i and acquired angioedema, and has symptoms including edema and peau d'orange. An important gene associated with Angioedema is F12 (Coagulation Factor XII), and among its related pathways/superpathways are Collagen chain trimerization and Peptide hormone metabolism. The drugs Histamine and Omalizumab have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and heart.

Wikipedia : 76 Angioedema is an area of swelling of the lower layer of skin and tissue just under the skin or mucous... more...

Related Diseases for Angioedema

Diseases in the Angioedema family:

Angioedema, Hereditary, Type I Angioedema, Hereditary, Type Iii
Hereditary Angioedema Acquired Angioedema
Acquired Angioedema Type 1 Acquired Angioedema Type 2

Diseases related to Angioedema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
# Related Disease Score Top Affiliating Genes
1 angioedema, hereditary, type i 34.7 F12 SERPING1
2 acquired angioedema 34.4 C1S SERPING1
3 hereditary angioedema 32.4 ACE BDKRB2 C1S F12 KLKB1 KNG1
4 c1 inhibitor deficiency 32.1 BDKRB2 C1S KLKB1 KNG1 SERPING1
5 allergic urticaria 30.4 KNG1 SERPING1
6 eosinophilia-myalgia syndrome 28.8 HNMT IL5
7 sinusitis 28.3 IL5 LTC4S
8 urticaria 27.5 C1S CPN1 F12 HNMT LTC4S PTGS1
9 angioedema, hereditary, type iii 12.5
10 angioedema induced by ace inhibitors 12.4
11 episodic angioedema with eosinophilia 12.3
12 acquired angioedema type 2 12.0
13 acquired angioedema type 1 11.8
14 vibratory urticaria 11.7
15 complement component 4, partial deficiency of 11.3
16 carboxypeptidase n deficiency 10.9
17 netherton syndrome 10.9
18 loiasis 10.9
19 peroneal neuropathy 10.3 CPN1 MME
20 type i 10.2
21 malignant essential hypertension 10.2 ACE KLKB1 KNG1
22 renal hypertension 10.2 ACE KLKB1 KNG1
23 laryngitis 10.1
24 lymphoma 10.1
25 lupus erythematosus 10.1
26 chronic tic disorder 10.1 F12 IL5
27 systemic lupus erythematosus 10.0
28 congestive heart failure 10.0 ACE KNG1 MME
29 endotheliitis 10.0
30 pancreatitis 9.9
31 thyroiditis 9.9
32 dermatitis 9.9
33 ischemia 9.9
34 aspirin resistance 9.9 PTGS1 PTGS2
35 aging 9.8
36 arthritis 9.8
37 physical urticaria 9.8
38 contact dermatitis 9.8
39 acute pancreatitis 9.8
40 depression 9.8
41 active peptic ulcer disease 9.8 PTGS1 PTGS2
42 leukemia, chronic lymphocytic 2 9.8
43 leukemia, chronic lymphocytic 9.8
44 macroglossia 9.8
45 helicobacter pylori infection 9.8
46 anxiety 9.8
47 autoimmune lymphoproliferative syndrome, type v 9.8
48 adult-onset still's disease 9.8
49 cheilitis 9.8
50 allergic contact dermatitis 9.8

Graphical network of the top 20 diseases related to Angioedema:



Diseases related to Angioedema

Symptoms & Phenotypes for Angioedema

UMLS symptoms related to Angioedema:


edema, peau d'orange

Drugs & Therapeutics for Angioedema

Drugs for Angioedema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 287)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 75614-87-8, 51-45-6 774
2
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 242138-07-4
3
Icatibant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 138614-30-9, 130308-48-4 71364
4
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
5
Loratadine Approved, Investigational Phase 4,Phase 2 79794-75-5 3957
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Everolimus Approved Phase 4 159351-69-6 6442177
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1 22916-47-8 4189
10
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
11
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
12
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6 23994
13
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
14
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
15
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
16
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
17
Pantoprazole Approved Phase 4 102625-70-7 4679
18
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
19
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
20
Enalapril Approved, Vet_approved Phase 4,Not Applicable 75847-73-3 5362032 40466924
21
Enalaprilat Approved Phase 4,Not Applicable 76420-72-9 6917719
22
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
23
Bradykinin Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-82-2 439201
24
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
25 Vaccines Phase 4,Phase 2
26 Kininogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
31
Histamine Phosphate Phase 4,Phase 2,Phase 3,Not Applicable 51-74-1 65513
32 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Complement C1 Inactivator Proteins Phase 4,Phase 3,Phase 2,Phase 1
39 Complement C1 Inhibitor Protein Phase 4,Phase 3,Phase 2,Phase 1
40 Complement C1s Phase 4,Phase 3,Phase 2,Phase 1
41 Complement Inactivating Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Complement System Proteins Phase 4,Phase 3,Phase 2,Phase 1
43 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
45 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
48 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Bradykinin B2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
50 Bradykinin Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 178)
# Name Status NCT ID Phase Drugs
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 A Call Center During HAE Attacks (SOS HAE) Completed NCT01679912 Phase 4
3 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE Completed NCT00914966 Phase 4
4 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed NCT01457430 Phase 4 Icatibant
5 Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Completed NCT01467947 Phase 4
6 Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria Completed NCT01444196 Phase 4 Desloratadine
7 Steroids in Fulminant Hepatic Failure in the Pediatric Age Group Completed NCT02375867 Phase 4 prednisolone;methylprednisolone
8 Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus Completed NCT00502242 Phase 4 ramipril;ramipril
9 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed NCT02550106 Phase 4 OMALIZUMAB
10 Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety Completed NCT00359801 Phase 4 Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care;Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
11 Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
12 Stress Ulcer Prophylaxis in the Intensive Care Unit Completed NCT02467621 Phase 4 Pantoprazole
13 Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women Completed NCT01937234 Phase 4 Metoclopramide;Placebo
14 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Recruiting NCT02966314 Phase 4 Omalizumab;Placebos
15 A Study to Evaluate the Benefit of RUCONEST® in Subjects With CVID Who Experience ADRs Related to IVIG Infusions Recruiting NCT03576469 Phase 4
16 Comparison of Saocubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure Episode. Recruiting NCT02554890 Phase 4 sacubitril/valsartan (LCZ696);Enalapril;sacubitril/valsartan (LCZ696) matching placebo;enalapril matching placebo
17 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema Terminated NCT01574248 Phase 4 icatibant
18 C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation Withdrawn NCT01151735 Phase 4 C-1-esterase;C-1-esterase;placebo
19 Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Completed NCT02586805 Phase 3 DX-2930 - 300mg/2wk;DX-2930 - 300mg/4wk;DX-2930 - 150mg/4wk;Placebo
20 A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Completed NCT01912456 Phase 3
21 Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema Completed NCT01919801 Phase 3 Icatibant;Placebo
22 Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy Completed NCT01723072 Phase 3 Placebo
23 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125151 Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
24 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125541 Phase 2, Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
25 Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema Completed NCT02052141 Phase 3
26 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00438815 Phase 3
27 Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Completed NCT02584959 Phase 3 C1 esterase inhibitor [human] liquid;Placebo
28 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00462709 Phase 3
29 A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema Completed NCT01386658 Phase 3 icatibant
30 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema Completed NCT00097695 Phase 3 Icatibant;Placebo
31 A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) Completed NCT00912093 Phase 3 Icatibant;Placebo
32 A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Completed NCT02316353 Phase 3
33 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks Completed NCT02303626 Phase 2, Phase 3 BCX4161;Placebo
34 Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) Completed NCT00456508 Phase 3 ecallantide
35 Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00457015 Phase 3 ecallantide;Phosphate Buffer Saline (PBS), pH 7.0
36 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00225147 Phase 2, Phase 3 Recombinant Human C1 Inhibitor;placebo
37 C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks Completed NCT01005888 Phase 3 Placebo (saline)
38 Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) Completed NCT02865720 Phase 3 CINRYZE 500 U;CINRYZE 1000 U
39 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00500656 Phase 3 Icatibant;Tranexamic Acid;Oral Placebo;S.C. Placebo
40 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262301 Phase 3 recombinant human C1 inhibitor;Placebo
41 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262288 Phase 2, Phase 3 i.v. recombinant human C1 inhibitor
42 C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) Completed NCT00292981 Phase 3 C1 Esterase Inhibitor
43 Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks Completed NCT01188564 Phase 3 rhC1INH;Placebo (Saline)
44 EASSI - Evaluation of the Safety of Self-Administration With Icatibant Completed NCT00997204 Phase 3 Icatibant
45 Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00262080 Phase 3 ecallantide;Phosphate Buffer Saline (PBS),
46 Berinert P Study of Subcutaneous Versus Intravenous Administration Completed NCT00748202 Phase 3 C1-Esterase Inhibitor
47 Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks Completed NCT00168103 Phase 2, Phase 3
48 C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks Completed NCT00289211 Phase 3 Placebo (saline)
49 AVE7688 in Patients With Mild to Moderate Blood Pressure Completed NCT00284128 Phase 2, Phase 3 AVE7688;Losartan-potassium
50 OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients Completed NCT02161562 Phase 3 omalizumab;omalizumab

Search NIH Clinical Center for Angioedema

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: angioedema

Genetic Tests for Angioedema

Anatomical Context for Angioedema

MalaCards organs/tissues related to Angioedema:

41
Skin, Tongue, Heart, Liver, Brain, Kidney, Endothelial

Publications for Angioedema

Articles related to Angioedema:

(show top 50) (show all 1406)
# Title Authors Year
1
Acquired angioedema in juvenile systemic lupus erythematosus: case-based review. ( 29951963 )
2018
2
Threshold-Stimulated Kallikrein Activity Distinguishes Bradykinin- From Histamine-Mediated Angioedema. ( 29957871 )
2018
3
Health-Related Quality-of-Life with Subcutaneous C1-inhibitor for Prevention of Attacks of Hereditary Angioedema. ( 29391286 )
2018
4
Efficacy of C1Inhibitor concentrate in hereditary angioedema with C1Inhibitor deficiency: analysis in the French Cohort. ( 29964227 )
2018
5
Hereditary angioedema due to C1-inhibitor deficiency in Macedonia: clinical characteristics, novel SERPING1 mutations and genetic factors modifying the clinical phenotype. ( 29513108 )
2018
6
Case report presenting the diagnostic challenges in a patient with recurrent acquired angioedema, antiphospholipid antibodies and undetectable C2 levels. ( 29881401 )
2018
7
Plasma Prekallikrein: Its Role in Hereditary Angioedema and Health and Disease. ( 29423395 )
2018
8
Canadian Physician Survey on the Medical Management of Hereditary Angioedema. ( 29958877 )
2018
9
A transcriptomics study of hereditary angioedema attacks. ( 29729940 )
2018
10
Food as a trigger for abdominal angioedema attacks in patients with hereditary angioedema. ( 29866145 )
2018
11
Evaluating satisfaction of patients with hereditary angioedema with their past and present treatments: Implications for future therapies. ( 29279063 )
2018
12
Severe angioedema of laryngeal inlet in a woman receiving telmisartan therapy undergoing breast conservation surgery. ( 29910501 )
2018
13
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2A study. ( 29688579 )
2018
14
Enalapril-Induced Angioedema: Two Case Reports in a Rural Health Facility in Kenya. ( 29974027 )
2018
15
Hereditary Angioedema with Normal C1 Inhibitor: Four Types and Counting. ( 29410040 )
2018
16
Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema. ( 29316335 )
2018
17
Impaired Endothelial Function in Hereditary Angioedema During the Symptom-Free Period. ( 29867566 )
2018
18
Plasminogen gene mutation with normal C1Inhibitor-hereditary angioedema: Three additional French families. ( 29952006 )
2018
19
SERPING1 and F12 combined variants in a hereditary angioedema family<sup>,,a9^a9^a9^,a9^a9^a9^a9^</sup>. ( 29885370 )
2018
20
Use of pdC1-INH concentrate for long-term prophylaxis during pregnancy in hereditary angioedema with normal C1-INH. ( 29439936 )
2018
21
Orolingual and abdominal angioedema post thrombolysis and thrombectomy. ( 29335305 )
2018
22
Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema. ( 29909591 )
2018
23
Acquired Angioedema With Anti-C1-inhibitor Autoantibodies During Assisted Reproduction Techniques. ( 29461216 )
2018
24
Angioedema Associated With Nebulized Recombinant Human DNase in a Preterm Infant: Case Report. ( 29970979 )
2018
25
Tired and Swollen: A Mono Mimic for Angioedema. ( 29920345 )
2018
26
Malassezia infection associated with chronic spontaneous urticaria without angioedema: a report on five cases. ( 29945261 )
2018
27
Severe allergic contact dermatitis mimicking angioedema caused by propolis used as a traditional remedy. ( 29845630 )
2018
28
Atypical presentation of acquired angioedema. ( 29554170 )
2018
29
ACE Inhibitor-Induced Angioedema: a Review. ( 29884969 )
2018
30
Clinical Features of Hereditary Angioedema in Korean Patients: A Nationwide Multicenter Study. ( 29694969 )
2018
31
The Incidence and Frequency of Various Causes of Angioedema in Emergency Medicine. ( 29957967 )
2018
32
Assessing the impact of the new ICD-10-CM coding system on pharmacoepidemiologic studies-An application to the known association between angiotensin-converting enzyme inhibitors and angioedema. ( 29947045 )
2018
33
Hereditary and Acquired Angioedema: Heterogeneity of Pathogenesis and Clinical Phenotypes. ( 29393169 )
2018
34
Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency. ( 29753808 )
2018
35
Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years. ( 29757016 )
2018
36
Amlodipine-induced angioedema: An unusual complication of a common medication. ( 29977650 )
2018
37
The international WAO/EAACI guideline for the management of hereditary angioedema - the 2017 revision and update. ( 29318628 )
2018
38
Hereditary Angioedema, Clinical Presentation and Socio-Economic Cost of 200 French Patients. ( 29936190 )
2018
39
Refractory Abdominal Pain in a Patient with Chronic Lymphocytic Leukemia: Be Wary of Acquired Angioedema due to C1 Esterase Inhibitor Deficiency. ( 29545957 )
2018
40
Investigational drugs in phase I and phase II clinical trials for hereditary angioedema. ( 29226721 )
2018
41
Improving the Management of Hereditary Angioedema. ( 29791522 )
2018
42
The Diagnosis of Hereditary Angioedema: Family Caregivers' Experiences. ( 29862835 )
2018
43
Presymptomatic genetic diagnosis of two siblings with hereditary angioedema, presenting with unusual normal levels of serum C4. ( 29058329 )
2018
44
Unilateral orolingual angioedema after thrombolysis in a patient with cerebrovascular ischemia. ( 29947878 )
2018
45
Hereditary angioedema: The plasma contact system out of control. ( 29920929 )
2018
46
A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor. ( 29548426 )
2018
47
Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks. ( 29954477 )
2018
48
Brazilian Guidelines for Hereditary Angioedema Management - 2017 Update Part 1: Definition, Classification and Diagnosis. ( 29723342 )
2018
49
New Treatments for Hereditary Angioedema. ( 29357215 )
2018
50
Idiopathic Nonhistaminergic Acquired Angioedema Versus Hereditary Angioedema. ( 29715562 )
2018

Variations for Angioedema

ClinVar genetic disease variations for Angioedema:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh37 Chromosome 5, 176831232: 176831232
2 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh38 Chromosome 5, 177404231: 177404231
3 SYTL2 NM_032943.4(SYTL2): c.890delG (p.Ser297Thrfs) deletion Pathogenic rs1057519445 GRCh38 Chromosome 11, 85734436: 85734436
4 SYTL2 NM_032943.4(SYTL2): c.890delG (p.Ser297Thrfs) deletion Pathogenic rs1057519445 GRCh37 Chromosome 11, 85445479: 85445479
5 SERPING1 NM_000062.2(SERPING1): c.1475T> C (p.Met492Thr) single nucleotide variant Likely pathogenic rs978962357 GRCh37 Chromosome 11, 57382026: 57382026
6 SERPING1 NM_000062.2(SERPING1): c.1475T> C (p.Met492Thr) single nucleotide variant Likely pathogenic rs978962357 GRCh38 Chromosome 11, 57614553: 57614553

Expression for Angioedema

Search GEO for disease gene expression data for Angioedema.

Pathways for Angioedema

Pathways related to Angioedema according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.46 DPP4 F12 KLKB1 KNG1 MME XPNPEP2
2
Show member pathways
11.97 ACE CPN1 DPP4 MME
3
Show member pathways
11.94 LTC4S PTGS1 PTGS2
4
Show member pathways
11.82 F12 KLKB1 KNG1 SERPING1
5
Show member pathways
11.7 LTC4S PTGS1 PTGS2
6 11.24 BDKRB2 C1S F12 KLKB1 KNG1 SERPING1
7 11.23 F12 KLKB1 SERPING1
8
Show member pathways
11.16 ACE BDKRB2 KNG1 MME
9 11.03 PTGS1 PTGS2
10 10.98 PTGS1 PTGS2
11
Show member pathways
10.96 PTGS1 PTGS2
12 10.87 ACE MME
13 10.86 PTGS1 PTGS2
14 10.76 PTGS1 PTGS2
15 10.71 LTC4S PTGS1 PTGS2
16 10.61 PTGS1 PTGS2

GO Terms for Angioedema

Cellular components related to Angioedema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 ACE C1S CPN1 F12 IL5 KLKB1
2 extracellular region GO:0005576 9.65 ACE C1S CPN1 DPP4 F12 IL5
3 extracellular exosome GO:0070062 9.36 ACE C1S DPP4 F12 HNMT KLKB1

Biological processes related to Angioedema according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 regulation of complement activation GO:0030449 9.77 C1S CPN1 SERPING1
2 blood coagulation GO:0007596 9.76 F12 KLKB1 KNG1 SERPING1
3 inflammatory response GO:0006954 9.73 BDKRB2 IL5 KLKB1 KNG1 PTGS1 PTGS2
4 cellular oxidant detoxification GO:0098869 9.67 LTC4S PTGS1 PTGS2
5 regulation of blood pressure GO:0008217 9.65 ACE PTGS1 PTGS2
6 arachidonic acid secretion GO:0050482 9.62 ACE BDKRB2
7 regulation of vasoconstriction GO:0019229 9.61 ACE BDKRB2
8 prostaglandin metabolic process GO:0006693 9.61 PTGS1 PTGS2
9 vasodilation GO:0042311 9.6 BDKRB2 KNG1
10 lipoxygenase pathway GO:0019372 9.58 LTC4S PTGS2
11 prostaglandin biosynthetic process GO:0001516 9.58 PTGS1 PTGS2
12 peptide metabolic process GO:0006518 9.57 CPN1 MME
13 amyloid-beta metabolic process GO:0050435 9.56 ACE MME
14 proteolysis GO:0006508 9.56 ACE C1S CPN1 DPP4 F12 KLKB1
15 zymogen activation GO:0031638 9.55 F12 KLKB1
16 regulation of blood coagulation GO:0030193 9.54 F12 SERPING1
17 angiotensin maturation GO:0002003 9.52 ACE MME
18 cyclooxygenase pathway GO:0019371 9.51 PTGS1 PTGS2
19 fibrinolysis GO:0042730 9.5 F12 KLKB1 SERPING1
20 hemostasis GO:0007599 9.46 F12 KLKB1 KNG1 SERPING1
21 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.43 BDKRB2 PTGS2
22 positive regulation of fibrinolysis GO:0051919 9.4 F12 KLKB1
23 Factor XII activation GO:0002542 9.37 F12 KLKB1
24 blood coagulation, intrinsic pathway GO:0007597 8.92 F12 KLKB1 KNG1 SERPING1

Molecular functions related to Angioedema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.97 ACE C1S CPN1 DPP4 F12 KLKB1
2 serine-type endopeptidase activity GO:0004252 9.71 C1S DPP4 F12 KLKB1
3 metallopeptidase activity GO:0008237 9.62 ACE CPN1 MME XPNPEP2
4 heme binding GO:0020037 9.61 KLKB1 PTGS1 PTGS2
5 aminopeptidase activity GO:0004177 9.48 DPP4 XPNPEP2
6 peroxidase activity GO:0004601 9.46 PTGS1 PTGS2
7 serine-type peptidase activity GO:0008236 9.46 C1S DPP4 F12 KLKB1
8 exopeptidase activity GO:0008238 9.26 ACE MME
9 peptidase activity GO:0008233 9.23 ACE C1S CPN1 DPP4 F12 KLKB1
10 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS1 PTGS2

Sources for Angioedema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....